Research
Hormonal
GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) significantly reduce the progression to type 2 diabetes and improve normoglycemia in prediabetic individuals, with effects partially sustained after withdrawal.
For individuals with prediabetes, GLP-1 receptor agonists like liraglutide, semaglutide, and tirzepatide are effective in preventing type 2 diabetes and restoring normal blood sugar levels. While some benefits may diminish after stopping the medication, the initial reduction in diabetes risk is significant.
GoodSupportsHIGH confidence
T2DM was less frequent among subjects on liraglutide, semaglutide and tirzepatide compared with the control arm. Delayed progression to T2DM has also been observed. Furthermore, normoglycaemia was achieved for subjects on liraglutide (up to 66%), semaglutide (up to 81%) and tirzepatide (up to 93.3%). However, this effect was only partially sustained following drug withdrawal.
Why this rating
Supported by multiple RCTs and post-hoc analyses of large trials (STEP10, SURMOUNT-1).
Source
Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes
Theodoros Panou et al. · Diabetes Therapy · 2026
DOI 10.1007/s13300-026-01865-5
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →